In summary, luteolin ameliorates experimental pulmonary arterial hypertension, and which exerts protective effects partly by reducing YAP nuclear localization and inhibiting the activation of the downstream PI3K/AKT pathway. The gene discussed is PIK3CB; the disease is pulmonary arterial hypertension.